1 line
21 KiB
Text
1 line
21 KiB
Text
|
{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T05:24:10Z","timestamp":1705641850834},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n <jats:title>Purpose<\/jats:title>\n <jats:p>Advances in therapy of metastatic castration-refractory prostate cancer (mCRPC) resulted in more therapeutic options and led to a higher need of predictive\/prognostic biomarkers. Systemic inflammatory biomarkers could provide the basis for personalized treatment selection. This study aimed to assess the modified Glasgow Prognostic Score (mGPS), the neutrophile-to-lymphocyte ratio (NLR), the platelet-to-lymphocyte ratio (PLR) and the systemic immune-inflammation index (SII) in men with mCRPC under docetaxel.<\/jats:p>\n <\/jats:sec><jats:sec>\n <jats:title>Methods<\/jats:title>\n <jats:p>Patients with mCRPC and taxane chemotherapy at a tertiary care centre between 2010 and 2019 were screened retrospectively. The biomarkers mGPS, NLR, PLR and SII were assessed and analyzed for biochemical\/radiologic response and survival.<\/jats:p>\n <\/jats:sec><jats:sec>\n <jats:title>Results<\/jats:title>\n <jats:p>We included 118 patients. Of these, 73 (61.9%) had received docetaxel as first-line, 31 (26.2%) as second-line and 14 (11.9%) as third-line treatment. For biochemical response, mGPS (odds ratio (OR) 0.54, <jats:italic>p<\/jats:italic>\u2009=\u20090.04) and PLR (OR 0.63, <jats:italic>p<\/jats:italic>\u2009=\u20090.04) were independent predictors in multivariable analysis. SII was significant in first-line cohort only (OR 0.29, <jats:italic>p<\/jats:italic>\u2009=\u20090.02). No inflammatory marker was predictive for radiologic response. In multivariable analysis, mGPS and NLR (hazard ratio (HR) 1.71 and 1.12, both <jats:italic>p<\/jats:italic>\u2009<\u20090.01) showed significant association with OS in total cohort and mGPS in the first-line cohort (HR 2.23, <jats:italic>p<\/jats:italic>\u2009<\u20090.01). Haemoglobin (Hb) and alkaline phosphatase (AP) showed several significant associations regarding 1\u00a0year, 3\u00a0year, OS and biochemical\/radiologic response.<\/jats:p>\n <\/jats:sec><jats:sec>\n <jats:title>Conclusions<\/jats:title>\n <jats:p>Pre-treatment mGPS seems a promising prognostic biomarker. A combination of mGPS, NLR and further routine markers (e.g., Hb and AP) could yield optimized stratification for treatment selection. Further prospective and multicentric assessment is needed.<\/jats:p>\n <\/jats:sec>","DOI":"10.1007\/s00432-022-04220-w","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T08:03:36Z","timestamp":1659945816000},"page":"3371-3381","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort"],"prefix":"10.1007","volume":"149","author":[{"given":"Manuel","family":"Neuberger","seque
|